News

/

/

/

CPhI India 2018, Booth No. 4.H15

News classification

Check category



News Center

Viwit Pharmaceutical’s Lifitegrast API has completed registrations in both China and the US! 2024-08-14 11:55:51

Recently, Viwit Pharmaceutical’s self-developed Lifitegrast API has completed the registrations in China and the United States. The API registration number is Y20240000726, and the US DMF number is 040172.

Viwit Pharmaceutical's Varenicline Tartrate Tablet receives official approval from South Africa 2024-07-15 10:01:41

Recently, theViwit independently developed smoking cessation drug Varenicline (Tartrate) Tablets, in strengths of 0.5 mg and 1 mg, received the Drug Registration Certificate issued by the South African Health Products Regulatory Authority (SAHPRA).

Viwit Pharmaceutical's Fosaprepitant Dimeglumine API Receives Official Approval from NMPA 2024-07-12 09:12:19

On July 5, 2024, Viwit Pharmaceitical’s independently developed Fosaprepitant Dimeglumine API received the "Notice of Approval of Application for Listing of Chemical APIs" issued by National Medical Products Administration (NMPA). The registration number is Y20220000736, and the notice number is 2024YS00664.

Viwit Pharmaceuticals' Bimatoprost Eye Drops Receive Official Approval by China NMPA 2024-07-09 10:54:01

Recently, Viwit Pharmaceuticals received the "Drug registration certificate" issued by China National Medical Products Administration (NMPA) for Bimatoprost Eye Drops. The approval number is H20244103. This signifies that the product has received official approval for the Chinese market and has successfully passed the generic drug consistency evaluation, thereby becoming the second domestic generic drug of its kind.

Viwit Pharmaceuticals' Gadoterate Meglumine Injection Receives Official Approval by China NMPA 2024-06-17 15:13:15

Viwit Pharmaceuticals proudly announces the receipt of the "Drug Supplementary Application Approval Notice" from the National Medical Products Administration (NMPA) for their Gadoterate Meglumine Injection. This approval includes the following strengths: 10 mL containing 3.769 g, 15 mL containing 5.654 g, and 20 mL containing 7.538 g. The corresponding approval numbers are H20243899, H20243900, and H20243901.

Viwit Pharmaceuticals' Deslanoside Injection Receives Official Approval by China NMPA 2024-06-15 10:26:00

May 8, 2024 – Viwit Pharmaceuticals proudly announces the receipt of the "Drug Supplementary Application Approval Notice" from the National Medical Products Administration (NMPA) for the drug product, Deslanoside Injection. The approval notice number is 2024B01980.

CPhI India 2018, Booth No. 4.H15

Categories:In 2018
Author:
Origin:
Time of issue:2018-12-12 01:34

(Summary description)CPhI India 2018, Booth No. 4.H15

CPhI India 2018 will take place on Dec. 12 - Dec. 14, 2018 at India Expo Center, India. Please visit us on CPhI India 2018, Booth No. 4.H15. If you would like to make an appointment, please send an e-mail to service@viwit.com.





CPhI India 2018, Booth No. 4.H15

(Summary description)CPhI India 2018, Booth No. 4.H15

CPhI India 2018 will take place on Dec. 12 - Dec. 14, 2018 at India Expo Center, India. Please visit us on CPhI India 2018, Booth No. 4.H15. If you would like to make an appointment, please send an e-mail to service@viwit.com.

Categories:In 2018
Author:
Origin:
Time of issue:2018-12-12 01:34
Views:

Information

CPhI India 2018, Booth No. 4.H15

CPhI India 2018 will take place on Dec. 12 - Dec. 14, 2018 at India Expo Center, India. Please visit us on CPhI India 2018, Booth No. 4.H15. If you would like to make an appointment, please send an e-mail to service@viwit.com.

Scan the QR code to read on your phone

Previous: None

Next: Welcome participants in CPhI India 2018, booth number: 4.H15

Previous: None

Next: Welcome participants in CPhI India 2018, booth number: 4.H15



search

Confirm

Close

About Us

R&D and Innovation

Products

Innovation

Sustainable

News Center

Join Us

Contact Us

VIWIT 沪ICP备12014533号-2 Terms of Use

EN

中文